Mitochondria-associated granulocyte-macrophage colony-stimulating factor signaling molecule (Magmas)

Mitochondria-associated granulocyte-macrophage colony-stimulating factor signaling molecule (Magmas), also known as PAM16, is a 13.8 kDa protein essential for mitochondrial function and cellular survival [1, 4]. It is primarily localized to the inner mitochondrial membrane as part of the presequence translocase-associated motor (PAM) within the TIM23 complex, where it regulates the import of nuclear-encoded proteins into the mitochondrial matrix [3, 6, 12]. Beyond its structural role in mitochondrial biogenesis, Magmas serves as a critical regulator of reactive oxygen species (ROS) homeostasis by enhancing antioxidant enzyme activity and scavenging ROS, thereby protecting cells from oxidative stress-induced damage [8, 10]. In clinical research, Magmas is frequently overexpressed in aggressive, treatment-resistant malignancies such as glioblastoma and prostate and ovarian cancers, where it promotes tumor progression and prevents apoptosis [1, 3, 10]. Therapeutic inhibition of Magmas using small molecules like BT#9 has demonstrated efficacy in inducing ROS-mediated cell death and resensitizing chemoresistant cancer cells, making it a promising target for novel oncological therapies [1, 14].

Other names

PAM16TIM16TIMM16CGI-136SMDMDMPresequence translocated-associated motor subunit PAM16Mitochondrial import inner membrane translocase subunit TIM16

Small molecule inhibition of Magmas leads to the disruption of the TIM23 translocase complex function and the accumulation of reactive oxygen species (ROS), which induces caspase-independent necrosis and mitochondrial dysfunction [1, 10].